DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell ...

Ari Rosenberg, an oncologist at the University of Chicago Medicine, has been trying to improve conditions for people being treated for oropharyngeal squamous cell carcinoma (OPSCC). Incidence of ...

Overall, the results showed that HPV-positive patients had a 40% higher likelihood of developing cardiovascular disease and twice the risk of developing coronary artery disease compared with HPV ...

The incidence of Human Papillomavirus (HPV)-associated oropharyngeal cancer tumors of the back of the mouth and throat is rising. If caught early, ...

The abstracts will showcase research on Versamune® HPV (PDS0101), particularly its effectiveness in treating HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma in ...